RECRUITINGPhase 3

Mebendazole as Adjuvant Treatment for Colon Cancer

mebendazole treating colon cancer

Sponsor

Sherief Abd-Elsalam

Enrollment

40 participants

Sites

1 locations

Start Date

April 2019

Completion

December 2028

Colorectal CancerFolfox with avastinMebendazole

Enrollment & Timeline

Recruiting

Target enrollment (estimated)

Target N

participants

Sites

locations

Duration

9.7 years

total trial span

Apr 2019Month 84 of 116Dec 2028

72% of trial timeline elapsed32 months to primary endpoint

Enrollment target is estimated. ClinicalTrials.gov does not provide real-time enrollment progress.

View on ClinicalTrials.gov

Ask AI

Primary Outcomes

number of patients with tumour response

6 months

number of patients with response

Ask AI

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer.

Hegazy Sahar K, El-Azab Gamal A, Zakaria Fatma et al.Life sciences2022

DOI PubMed

PubMed/NCBI (daily updates) FDA FAERS (quarterly updates) WHO ICTRP (weekly updates)

Ask AI

Fetching protocol from ClinicalTrials.gov…

RECRUITINGPhase 3

Mebendazole as Adjuvant Treatment for Colon Cancer

mebendazole treating colon cancer

Sponsor

Sherief Abd-Elsalam

Enrollment

40 participants

Sites

1 locations

Start Date

April 2019

Completion

December 2028

Colorectal CancerFolfox with avastinMebendazole

Enrollment & Timeline

Recruiting

Target enrollment (estimated)

Target N

participants

Sites

locations

Duration

9.7 years

total trial span

Apr 2019Month 84 of 116Dec 2028

72% of trial timeline elapsed32 months to primary endpoint

Enrollment target is estimated. ClinicalTrials.gov does not provide real-time enrollment progress.

View on ClinicalTrials.gov

Ask AI

Primary Outcomes

number of patients with tumour response

6 months

number of patients with response

Ask AI

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer.

Hegazy Sahar K, El-Azab Gamal A, Zakaria Fatma et al.Life sciences2022

DOI PubMed

PubMed/NCBI (daily updates) FDA FAERS (quarterly updates) WHO ICTRP (weekly updates)

Ask AI

Eligibility

Min Age

18 Years

Sex

all

Healthy Volunteers

View full criteria

Inclusion Criteria:

* Colorectal cancer stage 4.

Exclusion Criteria:

* Agranulocytosis
* Pregnancy
* Allergy to mebendazole.

Mebendazole as Adjuvant Treatment for Colon Cancer

Enrollment & Timeline

Primary Outcomes

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Mebendazole as Adjuvant Treatment for Colon Cancer

Enrollment & Timeline

Primary Outcomes

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Eligibility

Trial Sites (1)